Less can be more: The case for extended dosing intervals in biologic therapy for AD.
作者信息
Vestergaard Christian
机构信息
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
出版信息
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1070-1071. doi: 10.1111/jdv.20684.
Abstract
摘要
相似文献
1
Less can be more: The case for extended dosing intervals in biologic therapy for AD.少即是多：阿尔茨海默病生物治疗中延长给药间隔的情况。
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1070-1071. doi: 10.1111/jdv.20684.
2
Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis.患者报告的中度至重度斑块状银屑病生物治疗的治疗满意度及给药频率选择
Patient Prefer Adherence. 2015 Jun 16;9:777-84. doi: 10.2147/PPA.S85773. eCollection 2015.
3
Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents.评估延长给药间隔对青少年新冠mRNA疫苗有效性的影响。
Res Sq. 2024 Jun 18:rs.3.rs-4518813. doi: 10.21203/rs.3.rs-4518813/v1.
4
Exploring the use of extended release opioids at shortened dosing intervals in people with chronic pain and high risk medication or substance use.探讨在慢性疼痛且存在高药物/物质使用风险的人群中缩短给药间隔使用延长释放型阿片类药物的情况。
Int J Clin Pharm. 2021 Apr;43(2):404-410. doi: 10.1007/s11096-020-01027-y. Epub 2020 Sep 30.
5
Clinical Characteristics of Psoriasis Cases Treated by Biologics With an Extended Administration Interval: A Single-Center, Retrospective Observational Study.延长给药间隔的生物制剂治疗银屑病患者的临床特征：一项单中心回顾性观察研究
Cureus. 2024 May 9;16(5):e59969. doi: 10.7759/cureus.59969. eCollection 2024 May.
6
Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.稳定型银屑病患者生物制剂给药间隔的延长：一项可行性研究。
Ther Drug Monit. 2017 Aug;39(4):379-386. doi: 10.1097/FTD.0000000000000420.
7
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.与那他珠单抗延长给药方案相关的进行性多灶性白质脑病。
Neurodegener Dis Manag. 2015 Oct;5(5):399-402. doi: 10.2217/nmt.15.42. Epub 2015 Oct 30.
8
Clinical efficacy and safety of long-term treatment, discontinuation, and extended dosing intervals of denosumab treatment for solid cancer bone metastasis: A retrospective study.地诺单抗治疗实体癌骨转移的长期治疗、停药及延长给药间隔的临床疗效和安全性：一项回顾性研究。
J Orthop Sci. 2025 May 2. doi: 10.1016/j.jos.2025.04.012.
9
Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.慢性肾脏病合并贫血患者接受促红细胞生成素α或达比加群酯治疗时的给药间隔与血红蛋白控制：一项回顾性队列研究
Clin Ther. 2007 Sep;29(9):2010-21. doi: 10.1016/j.clinthera.2007.09.012.
10
Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis.生物制剂初治类风湿关节炎患者中生物制剂剂量超标者和非超标者的治疗模式。
J Manag Care Spec Pharm. 2017 Aug;23(8):798-808. doi: 10.18553/jmcp.2017.23.8.798.
本文引用的文献
1
Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how?增加特应性皮炎生物制剂的给药间隔——原因、对象、时间及方式？
J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1099-1107. doi: 10.1111/jdv.20534. Epub 2025 Jan 22.
2
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis.特应性皮炎III期和IV期临床试验中生物制剂的综合综述
J Clin Med. 2024 Jul 9;13(14):4001. doi: 10.3390/jcm13144001.
3
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.用于治疗特应性皮炎的生物制剂：现状与未来展望
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1053-1065. doi: 10.1016/j.jaip.2020.11.034.
4
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.欧洲皮肤病与性病学会/欧洲变态反应与临床免疫学会湿疹工作组2020年关于成人和儿童特应性皮炎诊断与治疗的立场文件。
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2717-2744. doi: 10.1111/jdv.16892. Epub 2020 Nov 17.
5
An approach for the transition from systemic immunosuppressants to dupilumab.一种从全身性免疫抑制剂过渡到度普利尤单抗的方法。
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e221-e223. doi: 10.1111/jdv.16941. Epub 2020 Oct 9.
Zotero 插件